menu
    • menu
    [{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orionis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"ChemDiv","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orionis Biosciences \/ Orionis Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Orionis Biosciences"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orionis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ORB-021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orionis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Orionis Biosciences \/ Cormorant Asset Management","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orionis Biosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":2.0499999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2.1099999999999999,"dosageForm":"Undisclosed","sponsorNew":"Orionis Biosciences \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Genentech"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Orionis Biosciences","amount2":2.1099999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":2.1099999999999999,"dosageForm":"Undisclosed","sponsorNew":"Orionis Biosciences \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Orionis Biosciences \/ Genentech"}]

    Find Clinical Drug Pipeline Developments & Deals by Orionis Biosciences

    Menu

    Orionis Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : $2,105.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orionis Partners With Genentech To Develop Molecular Glue Medicines for Cancer

                            Details : The collaboration with Genentech will enable Orionis to leverage its Allo-Glue platform for the discovery of small-molecule monovalent glue targets in major disease areas, including oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $105.0 million

                            May 21, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : $2,105.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORB-021

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORB-021 In Patients With Advanced Solid Tumors

                            Details : ORB-021 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : ORB-021

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : ChemDiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChemDiv Marks Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase 1 Trials

                            Details : ORB-011 is a cutting-edge attenuated, cis-targeted interferon immunotherapy compound. It is under phase 1 clinical development for the treatment of patients with advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2024

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : ChemDiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanc...

                            Details : ORB-011 is a clinical-stage, targeted interferon that is designed to specifically activate cDC1 dendritic cells, immune cells that are specialized in presenting tumor antigens to, and activating, tumor cytotoxic CD8 T cells.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 15, 2023

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Genentech

                            Deal Size : $2,047.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medici...

                            Details : The collaboration aims to discover novel small molecule monovalent medicines for challenging targets in major disease areas, including oncology and neurodegeneration by leveraging Orionis' Allo-Glue™ platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $47.0 million

                            September 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Genentech

                            Deal Size : $2,047.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORB-011 In Patients With Advanced Solid Tumors

                            Details : ORB-011 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : ORB-011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Can...

                            Details : Data demonstrated potent single-agent anti-tumor activity of immune cell-targeted interferons and interleukin-2 through remodeling of tumor microenvironments and cancer immunity cycle in syngeneic and humanized mouse models.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Orionis Biosciences

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cormorant Asset Management

                            Deal Size : $55.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic

                            Details : Orionis is rapidly advancing a deep pipeline of biologics for the treatment of cancer based on its A-Kine™ platform, which engineers target-selective, conditionally active cytokines designed to trigger anti-tumor immune responses even in “cold” tum...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cormorant Asset Management

                            Deal Size : $55.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth